Regulatory & Submissions · ANDA Support
ANDA Submission Support — CMC and Site Readiness
The short answer
Generic applications are decided as much on manufacturing quality and data credibility as on bioequivalence. We support the CMC content, the validation package and the data integrity posture of the site — the three areas where ANDA programs most often stall.
Why this matters
- Data integrity findings at a proposed manufacturing site can hold an application regardless of product quality.
- Exhibit batch and process validation documentation is examined for consistency with the commercial process described.
- Deficiency responses that restate the original submission add review cycles.
Applicable regulations and standards
- 21 CFR Part 314 Subpart C
- Abbreviated new drug application requirements.
- 21 CFR Part 211
- cGMP evaluated at the proposed manufacturing site.
- FDA Data Integrity and Compliance With CGMP Guidance
- Expectations for records, audit trails and system controls.
- ICH Q1A / Q2 / Q3
- Stability, analytical validation and impurity expectations.
What our consultants actually do
- Review and author CMC content for drug product and drug substance sourcing
- Assess exhibit batch documentation and its consistency with the commercial process
- Evaluate analytical method validation and transfer records
- Run data integrity assessments across laboratory and manufacturing systems
- Prepare the site for pre-approval inspection and remediate findings before filing
- Draft technical responses to CMC deficiency letters
Across the product lifecycle
01 / DEVELOP
Formulation and method development documented to support the filing.
02 / SCALE
Exhibit batches representative of commercial scale.
03 / TRANSFER
Method transfer to the release laboratory documented.
04 / VALIDATE
Process and cleaning validation completed and defensible.
05 / MANUFACTURE
Commercial production consistent with exhibit batch process.
06 / MAINTAIN
Annual reports, stability commitments and change control.
Problems we are usually called about
- Audit trail review not performed or not documented in the QC laboratory
- Exhibit batches manufactured on equipment that differs from the commercial train
- Cleaning validation limits without a documented toxicological basis
- Deficiency responses that argue rather than provide the requested data
Typical deliverables
- CMC technical review and authoring support
- Data integrity assessment with prioritized remediation
- Validation and method transfer gap assessment
- Pre-approval inspection readiness report
- Deficiency response drafting
Frequently asked
- Do you work with overseas manufacturing sites?
- Yes — most often assessing the site's readiness for a US pre-approval inspection and the credibility of its records. Where the question becomes international registration strategy, that belongs with GlobalRegulatory.com.
- What is the most common ANDA-stage problem you see?
- Laboratory data practices. Not fraud — usually undocumented review, shared logins and unreviewed audit trails that make good data hard to defend.
References
More for regulatory & submissions
Technical, manufacturing and quality support for US FDA submissions — written by people who have reviewed and inspected against them.
- 510(k) SupportA 510(k) is an argument for substantial equivalence, supported by evidence your quality system has to be able to produce on demand.
- PMA SupportA PMA is reviewed alongside a pre-approval inspection of the manufacturing site, which means the manufacturing section is not paperwork — it is a description of a facility that will be examined.
- De Novo SupportA De Novo asks FDA to create a classification, which means the submission has to propose the controls that will make the device type safe and effective.
- IND SupportFor an IND, the section that most often holds up a program is CMC.
- NDA SupportBy NDA, the manufacturing story has to be complete: a justified control strategy, validated process, qualified methods and a site that can demonstrate all of it during a pre-approval inspection.
- BLA SupportFor a biologic, the process is a substantial part of the product.
- IDE SupportAn IDE requires a description of how the investigational device is made and controlled, and design controls apply even though the device is not yet cleared.
Start a project
Tell us what you're working on.
Describe the product, the process or the problem. We will tell you honestly whether we are the right people to help, and who should be on the team if we are.